Transplant News and Research

RSS

New non-embryonic stem cell treatment for cancer and leukaemia

A monumental discovery that provides the promise of a cure not only for leukaemia, but cancer at large was announced this morning in London during GIL 2012: Europe. Steve Shor, the founder of the National Children's Leukemia Foundation, a leading non-profit organisation in the United States, unveiled a ground-breaking therapy his research teams in the United States and Israel have discovered.

10 May 2012

Dead skin donors come to the aid of a 92 year old with severe skin ulcers

A great grandmother is the first person in Britain to have a wound healed using skin from dead donors.

9 May 2012

More teenagers and young adults diagnosed with skin cancer

With summer just around the corner, pediatricians at Johns Hopkins Children's Center are sounding the alarm on a disturbing trend: A growing number of teenagers and young adults diagnosed with skin cancer.

8 May 2012

FDA approves Clinigen’s Foscavir sNDA to treat HIV/AIDS-related CMV infections and herpes

Clinigen Healthcare, the pharmaceutical products division of Clinigen Group, announced today that its supplemental new drug application (sNDA) for Foscavir (foscarnet sodium), a treatment for HIV/AIDS-related cytomegalovirus (CMV) infections and herpes, has been approved by the US Food and Drug Administration.

From Clinigen Group 8 May 2012

Research reveals possible strategy to reverse fibrosis in liver and other organs

An international team of scientists, led by researchers at the University of California, San Diego School of Medicine, report that significant numbers of myofibroblasts - cells that produce the fibrous scarring in chronic liver injury - revert to an inactive phenotype as the liver heals. The discovery in mouse models could ultimately help lead to new human therapies for reversing fibrosis in the liver, and in other organs like the lungs and kidneys.

8 May 2012

Walgreens acquires certain assets of BioScrip

Walgreen Co. today announced that it has completed its acquisition of certain assets of BioScrip, Inc.'s community specialty pharmacies and centralized specialty and mail service pharmacy businesses.

7 May 2012

Seattle Children's Hospital performs 100th heart transplant on 5-month-old baby

On Saturday, April 28, a 5-month-old baby received the 100th heart transplant performed at Seattle Children's Hospital, a significant milestone for him as well as the hospital's Heart Center and Heart Transplant Program teams.

7 May 2012

Accentia, Johns Hopkins co-host meeting with prospective clinical trial investigators at AAN meeting

Accentia Biopharmaceuticals, Inc. today announced that the Company and leading physicians from Johns Hopkins University co-hosted a meeting with prospective clinical trial investigators at the recent American Academy of Neurology (AAN) Annual Meeting in New Orleans.

7 May 2012

Human stem cells effective in treating muscular dystrophy

Researchers from the University of Minnesota's Lillehei Heart Institute have effectively treated muscular dystrophy in mice using human stem cells derived from a new process that - for the first time - makes the production of human muscle cells from stem cells efficient and effective.

5 May 2012

Alnylam first quarter revenues decrease to $20.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter 2012, and company highlights.

4 May 2012

Incentives increase blood drive donations

Blood drives do better with incentives, says University of Toronto study.

3 May 2012

Rigel first quarter net loss increases to $23.2 million

Rigel Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2012.

2 May 2012

Bevacizumab equivalent to ranibizumab in treating wet AMD

In a landmark drug-comparison study, Cleveland Clinic researchers found that bevacizumab (Avastin) is equivalent to ranibizumab (Lucentis) in the treatment of wet age-related macular degeneration (AMD) through two years.

2 May 2012

Synthetic stool transplant for C. difficile treatment

A synthetic mixture of intestinal bacteria could one day replace stool transplants as a treatment for Clostridium difficile (C. difficile). C. difficile is a toxin-producing bacteria that can overpopulate the colon when antibiotics eradicate other, naturally protective bacteria living there.

2 May 2012

Novel technique helps surgeons to remove 'inoperable' abdominal tumors

Abdominal tumors involving both roots of the celiac and superior mesenteric artery (SMA) are deemed unresectable by conventional surgical methods, as removal would cause necrosis of the organs that are supplied by those blood vessels.

2 May 2012

54% doctors support denying treatment to smokers and the obese until they quit or lose weight

Doctors.net.uk, a professional networking site, found that 593 (54%) of the 1,096 doctors who took part in the self-selecting survey answered yes when asked: “Should the NHS be allowed to refuse non-emergency treatments to patients unless they lose weight or stop smoking?” They believe unhealthy behaviour can make procedures less likely to work, and that the service is not obliged to devote scarce resources to them.

30 Apr 2012

Teens with high levels of uric acid at increased risk for high blood pressure

Teens with high levels of uric acid appear to be at increased risk for high blood pressure, according to results of research from scientists at the Johns Hopkins Children's Center.

30 Apr 2012

Hologic enters definitive agreement to acquire Gen-Probe

Hologic, Inc. and Gen-Probe Incorporated today announced that their Boards of Directors have unanimously approved a definitive agreement under which Hologic will acquire all of the outstanding shares of Gen-Probe for $82.75 per share in cash, or a total enterprise value of approximately $3.7 billion.

From Hologic, Inc. 30 Apr 2012

After hours and weekend transplants do not adversely affect patient or graft survival

A new study, funded in part by a grant from the National Institutes of Health (NIH), shows that liver transplants performed at night or on weekends do not adversely affect patient or graft survival. Findings available in the May issue of Liver Transplantation, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases, demonstrate that safety measures in place are working to protect patients.

27 Apr 2012

Share 35 policy reduces racial disparities in kidney transplantation among children

A policy instituted in 2005 has reduced racial disparities in kidney transplantation among children, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

27 Apr 2012